A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
about
Human antibody responses after dengue virus infection are highly cross-reactive to Zika virusDengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika VirusRecovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse VirulencePrecisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody ResponsesDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityMapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and VaccinationIdentifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus SpeciesA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisA Reverse Genetics Platform That Spans the Zika Virus Family TreeLack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus InfectionZika virus-like particle (VLP) based vaccineIn Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level.Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.Epitope Addition and Ablation via Manipulation of a Dengue Virus Serotype 1 Infectious CloneRecent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure.Immune correlates of protection for dengue: State of the art and research agenda.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.Efficient Reverse Genetic Systems for Rapid Genetic Manipulation of Emergent and Preemergent Infectious Coronaviruses.Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.CD-loop extension in Zika virus envelope protein key for stability and pathogenesis.Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III.Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties.Development of Antibody Therapeutics against Flaviviruses.Diagnosis of Zika Virus Infections: Challenges and Opportunities.The use of longitudinal cohorts for studies of dengue viral pathogenesis and protection.Physiological temperatures reduce dimerization of dengue and Zika virus recombinant envelope proteins.Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials
P2860
Q25161212-546F9063-3C4C-49B7-B4F2-D6A36FE14790Q26247258-2777EA3C-5070-46C9-B7DE-BD9A817FAE43Q27469118-9EB9D059-56F6-4B1D-8284-E219549088BDQ27493140-F5FF055C-D2F0-4873-A654-52DC3AB2D63AQ27654848-33150410-07C6-4003-8168-26504E84765CQ28114614-8048BFED-9A92-467F-BA97-3F5170EA6861Q28119651-8A076A80-D94F-4BFB-82F6-38FDD2ABC9FAQ28804076-90A78B5A-F2B5-480F-A0A8-19DFDA505101Q28954816-87110C08-49BD-492C-8DC8-C2DA2B6D3D7AQ29051494-B3E5966C-54AC-4199-BC8D-299BDCA9465AQ30145640-1FDC41E9-09B0-46D1-88AA-4D600C51E6F5Q33867337-261769DE-ADF6-4BEC-8E3F-F00EC86A39E6Q36327441-9F7F484A-6D71-440E-ACAE-DA3FD5EAA72CQ36878970-7B0E416B-E8E6-4E63-A3D5-2A1408B4DF15Q37661008-2E44AA1C-457C-4DCF-9DAE-708F617B768DQ38158407-B4A1C3B5-4DFB-4E96-ACD6-7272DE2667B0Q38652971-EDD4289D-D04E-4796-B528-B4506CE2115AQ39535403-A3BDAD2E-97DE-4D30-9DA2-8D22528FF0DEQ40047887-57A67FB5-3C56-4073-A4D9-0F3E1F82249CQ40200075-CC54435E-5DB7-42CC-97B7-88FEA0BA44C9Q41676281-2BD212F8-9634-4450-916C-0754D5959A62Q41918216-946C1945-36BC-4987-AC51-530459C0EFEFQ41919737-E79EF7DF-2B04-4E7F-8315-811BE0572E75Q45323668-0D1358B5-A5D6-4C56-85A7-0B11BDFC58B3Q47265866-77D83E49-AEEB-4131-B57D-2F861B001022Q47558158-6754CF3E-43AD-4823-9BBE-CEFFAE4B560EQ47558325-0DFD79C0-6BAD-4F8D-846C-B64951F6AEDFQ51782689-E9C8844E-D0DE-423E-B4BF-06A673356FC4Q54231305-ACF34CF0-E475-4FBF-903D-C2FFFF9A6BBEQ54266527-F39A7BF9-3F3B-4469-9909-A2969BBAF319Q58367215-7F5EBBAB-AB92-43E5-BBF9-5FC64028CC99
P2860
A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A new quaternary structure epi ...... cific neutralizing antibodies.
@ast
A new quaternary structure epi ...... cific neutralizing antibodies.
@en
type
label
A new quaternary structure epi ...... cific neutralizing antibodies.
@ast
A new quaternary structure epi ...... cific neutralizing antibodies.
@en
prefLabel
A new quaternary structure epi ...... cific neutralizing antibodies.
@ast
A new quaternary structure epi ...... cific neutralizing antibodies.
@en
P2093
P2860
P356
P1433
P1476
A new quaternary structure epi ...... cific neutralizing antibodies.
@en
P2093
A M de Silva
C A Sariol
E N Gallichotte
S Whitehead
W M Wahala
P2860
P304
P356
10.1128/MBIO.01461-15
P577
2015-10-13T00:00:00Z